Congressional Investigator Faults FDA Office of Chief Counsel
A senior investigator for the House Energy and Commerce Committee testified at an April 29 hearing that FDA's Office of Chief Counsel had thwarted a Congressional investigation into heparin contamination in China. David Nelson said the OCC refused to provide documents relating to FDA's inspection process and would not let investigators interview OCC staff attorneys
You may also be interested in...
Tucked away on the sixth floor of the Parklawn Building in Rockville, FDA's Office of Chief Counsel is calm and quiet. Beneath the surface, however, there is a surge of activity. One of the main engines driving the agency, the 80-lawyer shop helps craft regulations, manages dozens of lawsuits and oversees every enforcement action
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.